Advertisement

Journal of Bioethical Inquiry

, Volume 12, Issue 1, pp 19–20 | Cite as

Situating the Trovan Trial With the Use of Experimental Ebola Therapies Is Like Comparing an Apple With an Orange

  • Muhammed O. Afolabi
Letter to the Editor
  • 294 Downloads

I read with great bewilderment the unconvincing arguments of Peter F. Omonzejele (2014) in his article “Ethical Challenges Posed by the Ebola Virus Epidemic in West Africa” published in the 11(4) issue of the Journal of Bioethical Inquiry. While the author glaringly mixed up anthropological issues concerning the hygiene of hand-washing and safe burials in an article with a title clearly focused on ethical challenges, he failed to establish how the current Ebola epidemic ravaging some West Africa countries made these human practices ethical challenges. Anecdotal examples cited in the article fit entirely into the realm of anthropological and sociological issues fuelling the spread of Ebola but are not in any way related to ethical challenges. The title was either misleading or the author deliberately discussed anthropological/sociological issues tangentially in an article supposedly written on ethical issues.

The author also contradicted himself, having categorized as a compelling need...

Keywords

Meningitis Ethical Challenge Trovafloxacin Investigational Agent Meningitic Belt 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Adebamowo, C., O. Bah-Sow, F. Binka, et al. 2014. Randomised controlled trials for Ebola: Practical and ethical issues. The Lancet 384(9952): 1423–1424.CrossRefGoogle Scholar
  2. Folayan, M., B. Brown, A. Yakubu, K. Peterson, and B. Haire. 2014. Compassionate use of experimental drugs in the Ebola outbreak. The Lancet 384(9957): 1843–1844.CrossRefGoogle Scholar
  3. Hossain, M.J., A. Roca, G.A. Mackenzie, et al. 2013. Serogroup W135 meningococcal disease, The Gambia, 2012. Emerging Infectious Diseases 19(9): 1507–1510.CrossRefPubMedCentralPubMedGoogle Scholar
  4. Kanapathipillai, R., A.M.H. Restrepo, P. Fast, et al. 2014. Ebola vaccine—an urgent international priority. The New England Journal of Medicine 371(24): 2249–2251. doi: 10.1056/NEJMp1412166.CrossRefPubMedGoogle Scholar
  5. Lenzer, J. 2006. Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests. BMJ 332(7552): 1233.CrossRefPubMedCentralPubMedGoogle Scholar
  6. Lenzer, J. 2011. Pfizer settles with victims of Nigerian drug trial. BMJ 343: d5268. doi: 10.1136/bmj.d5268.CrossRefPubMedGoogle Scholar
  7. Maurice, J. 2014. WHO meeting chooses untried interventions to defeat Ebola. The Lancet 384(9948): e45–e46.CrossRefGoogle Scholar
  8. Omonzejele, P.F. 2014. Ethical challenges posed by the Ebola virus epidemic in West Africa. Journal of Bioethical Inquiry 11(4): 417–420.CrossRefPubMedGoogle Scholar
  9. Rid, A., and E.J. Emanuel. 2014. Ethical considerations of experimental interventions in the Ebola outbreak. The Lancet 384(9957): 1896–1899.CrossRefGoogle Scholar
  10. World Health Organization [WHO]. 2014. Potential Ebola therapies and vaccines. World Health Organization, November 5. http://apps.who.int/iris/bitstream/10665/137590/1/WHO_EVD_HIS_EMP_14.1_eng.pdf?ua=1. Accessed November 16, 2014.

Copyright information

© Journal of Bioethical Inquiry Pty Ltd. 2015

Authors and Affiliations

  1. 1.Medical Research Council Unit, FajaraBanjulWest Africa

Personalised recommendations